BioSpace News Archive

Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the virtual 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021, at 5:25 p.m. ET.

Progenity , Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced preliminary results, subject to final audited study reports by its contract research organization (CRO), from two key studies for the Company’s Targeted Therapeutics program. The studies involved both the first functional clinical study of the Drug Delivery System (DDS), and the first preclinical study of PGN-600 (liquid tofacitinib delivered by DDS), one of the Co

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease, allergy and opioid overdose, today announced that it will host an investor conference call on Monday, May 17, 2021 at 2 p.m. Pacific Time to discuss its financial and operating results for the first quarter of 2021 as well as provide a business update.

Inflarx announced today financial results for the three months ended March 31, 2021.

TMS-007 has the potential to be a next generation thrombolytic with an improved benefit-risk profile Acute ischemic stroke is caused by a blockage of blood supply to the brain, and current thrombolytics are limited in use due in part to increased risks of bleeding Phase 2a study demonstrated positive impacts on blood vessel reopening and patient functional recovery with no incidence of symptomatic intracranial hemorrhage

AngioSoma, Inc. (OTC PINK:SOAN) has added Robert Chicoski as its Chief Financial Officer and Treasurer. Chicoski has decades of corporate financial, tax, audit and forensic accounting experience to the AngioSoma team. Headquartered in Richland, Washington, AngioSoma, Inc. is a fast-growing company focused on providing medical research, development and treatment

Trial Will Evaluate Progesterone Receptor ONA-XR in Combination with Antiestrogen to Determine Potential of Complete Hormone Blockade on Endometrial Cancer Outcomes

Two-year grant awarded by the Hong Kong Government’s Innovation and Technology Commission is funding the development of new bispecific antibodies targeting NRP2

Alume Biosciences, Inc., a clinical stage biotechnology company developing nerve-targeted pharmaceuticals for surgical and therapeutic use, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead compound ALM-488.

Leap Therapeutics (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, and Flagship Biosciences , the leader in data-centric pathology and tissue analysis, today announced that they have developed an image analysis RNAscope ® assay that is being used successfully